Question 7305 — maternity health insurance

Summary

Ms. Florence Herouin-Léautey draws the attention of the Minister to the Minister of Labor, Health, Solidarity and Families, responsible for health and access to care, to the non-coverage of anti-calcitonin gene peptide (CGRP) monoclonal antibodies and in particular Emgality (galcanezumab) for people suffering from chronic migraines and cluster headaches (AVF). These diseases hamper the lives of people who suffer from it with an alteration of the quality of life and a financial cost. It is estimated that in France, more than 150,000 people live with severe migraine pain, undergoing on average ten years of medical wandering before finding suitable treatment. The World Health Organization (WHO) states that long-term efforts to live with chronic headaches may also predispose the subject to other illnesses such as anxiety and depression. The Emgality treatment (galcanezumab) has demonstrated its effectiveness in preventing chronic migraines but also in the treatment of cluster headaches. The MP highlights that 23 European countries have recognized the need to reimburse these innovative treatments. A group of which France is not part, considerably reducing the accessibility of this treatment. The WHO also emphasizes that the direct costs of treatment are low compared to the considerable indirect savings that could be made if resources were devoted to the correct treatment of these neurological conditions. Thus, many neurologists, patient associations and citizen groups have been calling for strong commitment from public authorities for months. As such, she wishes to know the measures that the State plans to implement to allow reimbursement of anti-CGRP monoclonal antibodies.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.